Every 3 seconds,
a new case of dementia is diagnosed worldwide!
We are developing a new approach
that could transform the lives of patients
affected by Alzheimer’s.
Our mission
Every three seconds, a new case of dementia is diagnosed worldwide, with Alzheimer’s disease accounting for more than two-thirds of these cases.
At SYNAPTYS neuroscience, our mission is to slow the progression of this neurodegenerative disease, bringing new hope to the millions of people affected and their families.
We are committed to transforming the lives of Alzheimer’s patient and their families through our innovative approach.
SYS-0108, our therapeutic solution
Alzheimer’s disease was described as the “epidemic of the century” at the AD-PD Congress in Lisbon in March 2024. It presents a tremendous challenge, not only due to the growing number of patients but also because there is currently no satisfactory treatment.
Our solution, SYS-0108, could change that. Rather than targeting a single mechanism like other research pathways to date, we have developed an innovative combination of drugs with multiple modes of action. We believe this approach is essential for treating this mutifactorial disease.
We have applied a method called “boosting”, used in artificial intelligence, to enhance the effectiveness of the molecules through synergy.
Currently in the preclinical phase, our approach aims to transform the course of Alzheimer’s disease and improve the lives of patients as well as their families.
Years
of scientific research
Committed researchers
(US, Canada, France, and Spain)
More than 20 publications validating our approach
A hope for Alzheimer’s patients
Living with Alzheimer’s disease or supporting a loved one is a daily challenge.
At SYNAPTYS neuroscience, we are developing an innovative solution to slow the progression of the disease and sustainably stabilize cognitive functions, thereby preserving the quality of life for patients. Through years of research, our treatment targets the neuronal mechanisms responsible for cognitive disorders, acting before the formation of the typical hallmarks of the disease (senile plaques and neurofibrillary degeneration).
Our partners
We are proud to collaborate with a diverse network of academic, institutional, and private partners who share our vision of innovation in the fight against Alzheimer’s disease. These collaborations are essential for enriching our research, strengthening our expertise, and accelerating the development of effective therapeutic solutions. Together, we are committed to advancing science and transforming the lives of those affected by this disease.
Stay informed about the progress of our research!